Biorelevant in vitro platform for enhanced micronutrient bioavailability
BioNotus introduces a biorelevant in vitro platform using Physiology-Based BioNeutraceutics Modelling to enhance micronutrient bioavailability. This cost-effective solution integrates in vitro and in silico methods to optimize formulation strategies and support decision making.
Overview
BioNotus presents an innovative biorelevant in vitro platform designed to significantly enhance the bioavailability of micronutrients. This platform utilizes a novel approach called Physiology-Based BioNeutraceutics Modelling (PBBM), which integrates in vitro in vivo correlation (IVIVC) with in silico modeling. The solution addresses the high costs and insufficient data associated with traditional in vivo and in vitro studies by providing a cost-effective alternative that supports decision making and optimal formulation strategies.
Technical specifications
Key features:
- In vitro in vivo correlation (IVIVC): Enhances the predictive accuracy of in vitro studies by simulating real physiological conditions.
- Physiology-Based BioNeutraceutics Modelling (PBBM): Utilizes established biopharmaceutics concepts to optimize micronutrient formulation strategies.
- In silico integration: Facilitates the translation of in vitro data into predictive in vivo simulations, ensuring comprehensive decision support.
- Biofluid selection: Customized selection of biofluids based on specific absorption pathways and nutritional states (fed or non-fed).
Technology readiness level
The biorelevant in vitro platform is currently at Technology Readiness Level 3. This indicates that the platform has been validated at the experimental proof of concept level, with further optimization and validation planned for in vitro assay optimization and relevant in vivo simulations.
About BioNotus
BioNotus is a GLP-certified contract research organization based in Niel, Belgium, that specializes in providing integrated solutions for drug discovery and development. Founded in 2017, the company offers a unique, combined portfolio of services encompassing bioanalysis, pharmacometrics, and discovery ADMET profiling. Its laboratory is equipped for LC-MS/MS-based bioanalysis to quantify drugs, metabolites, and biomarkers in diverse biological matrices, while its pharmacometrics division utilizes computational modeling and simulation, including population and physiology-based pharmacokinetic (PBPK) approaches, to guide clinical study design and dosing strategies. By offering both laboratory and consulting capabilities under one roof, BioNotus aims to enhance project efficiency and data-driven decision-making for its clients.
The company serves a wide range of partners, including university hospitals, academic researchers, and small-to-medium-sized pharmaceutical and biotech firms. By converting complex experimental data into actionable insights, BioNotus helps clients navigate regulatory requirements, optimize dosing in special populations, and improve the success rates of preclinical and clinical trials. Their approach emphasizes fit-for-purpose solutions and iterative integration of bioanalytical data with predictive modeling, providing customers with affordable, high-quality support that spans the entire lifecycle of drug development from early discovery stages to late-stage clinical evaluation.
Inquire about this partnering listing
Industry applications
delivered to your inbox.